The mechanisms underlying how arsenic methylation capacity affects bladder cancer (BC) are still unclear. The objective of this study was to explore the effects of polymorphisms of arsenic (þ3 oxidation state) methyltransferase (AS3MT) on BC risk. We conducted a hospital-based study and enrolled 216 BC and 648 healthy controls from 2007 to 2011. Urinary arsenic profiles were measured using high-performance liquid chromatography-hydride generation-atomic absorption spectrometry. The gene polymorphisms of AS3MT were identified using the Sequenom MassARRAY platform with iPLEX Gold chemistry. Inefficient arsenic methylation capacity (high monomethylarsonic acid percentage [MMA%] and low dimethylarsinic acid percentage [DMA%]) was associated with increased risk of BC in a dose-response relationship.
The International Agency for Research on Cancer has declared that inorganic arsenic is a carcinogen that can cause skin cancer and lung cancer in humans (IARC, 2012) . Chronic inorganic arsenic exposure is a global health issue, and it is associated with increased risk of skin, lung, bladder, and kidney cancers (Chen et al., 1988; Smith et al., 1992) . Bladder cancer (BC) is the most common malignancy involving the urinary system, and the predominant histological type was reported to be urothelial carcinoma (UC) in Taiwan in 2012, with an age-standardized incidence rate of 7.96/10 6 (Chiang et al., 2016) . Our previous study found a dose-response relationship between long-term arsenic exposure from drinking artesian well water and the incidence of BC in an arseniasis endemic area (Chiou et al., 1995) . A recent ecological study also reported an association between low water arsenic concentrations and BC incidence in the United States (Mendez et al., 2017) . In addition, a large perspective cohort in an agricultural health insurance scheme in France found that agricultural arsenic exposure (Boulanger et al., 2017) leads to the occurrence of BC. These lines of evidence support that different exposure routes and exposure concentrations of inorganic arsenic are associated with BC. Once inorganic arsenic enters the human body, arsenate (As V ) is reduced to arsenite (As III ), which then undergoes methylation to monomethylarsonic acid (MMA V ) and dimethylarsinic acid (DMA V ). These arsenic acids are then rapidly excreted in the urine (Vahter, 2002) . Traditionally, methylation of inorganic arsenic has been considered a detoxification mechanism, but in vitro studies have confirmed that the trivalent intermediates of monomethylarsonous acid (MMA III ) and dimethylarsinous acid (DMA III ) are more toxic than inorganic arsenite (Petrick et al., 2000; Styblo et al., 2002) , but this is difficult to measure in field studies. Epidemiological studies continue to point out that UC, BC, skin cancer, and peripheral vascular disease are associated with low arsenic methylation capacity (with high MMA V % or low DMA V %) (Chen et al., 2003a,b; Pu et al., 2007; Tseng et al., 2005) . In Taiwan, a significant dose-response relationship between combined effect of high cumulative arsenic exposure and high MMA V % or low DMA V % and increased risk of UC was found in an endemic arseniasis area (Huang et al., 2008a) . UC cases had a significantly higher sum of all the urinary species measured, higher MMA V % and lower DMA V %, compared with controls in an area with no evident arsenic exposure (Huang et al., 2008b; Pu et al., 2007) . These investigations suggested that individuals with inefficient arsenic methylation capacity may be susceptible to the risk of UC. However, these papers, integrated into UC for discussion, did not discuss upper tract urothelial carcinoma (UTUC) and BC separately. Specific risk factors of UTUC, such as regular consumption of the analgesic drug phenacetin and Chinese herbal products containing aristolochic acid, are different from those of BC (Colin et al., 2009) . In this study, we excluded UTUC to explore whether poor arsenic methylation capacity was related to an increased odds ratio (OR) of BC.
Genetic polymorphisms may influence the efficiency of arsenic metabolism (Agusa et al., 2011; Tellez-Plaza et al., 2013) and strongly affect susceptibility to disease (Antonelli et al., 2014) . The reduction of arsenate to arsenite or MMA V to MMA III is catalyzed by 2 enzymes, namely glutathione-S-transferase omegas (GSTOs) (Zakharyan et al., 2001 ) and purine nucleoside phosphorylase (PNP) (Radabaugh et al., 2002) . The methylation of trivalent arsenic is catalyzed by arsenic (þ3 oxidation state) methyltransferase (AS3MT), using S-adenosylmethionine as the methyl group donor (Thomas et al., 2007) . Some studies have discussed the association between polymorphisms of AS3MT and GSTO and arsenic methylation capacity between different populations (de la Rosa et al., 2017; Fu et al., 2014) . However, the available data on PNP polymorphisms are limited (Antonelli et al., 2014) , where only 1 study found that different levels of DMA% were seen in different PNP genotypes (rs1760940 vs rs1713420) (Chung et al., 2009) . A Chilean study reported that individuals with AS3MT rs3740393 minor allele had low MMA%, high DMA%, and low OR for BC (de la Rosa et al., 2017) . Our recent study also found that polymorphisms and haplotypes of the AS3MT gene were associated with developmental delay of children, but that GSTO and PNP polymorphisms were not (Hsieh et al., 2017) . The results of studies exploring the association between polymorphisms of AS3MT and disease are inconsistent.
The mechanisms underlying how arsenic methylation capacity affects BC are still unclear. Therefore, we conducted a hospital-based study to evaluate the association between AS3MT polymorphisms and BC. In addition, we examined whether AS3MT gene polymorphism modified the association between arsenic methylation capacity and BC.
MATERIALS AND METHODS
Study participants. A detailed protocol of participant recruitment was described in a previous study (Pu et al., 2007) . A hospitalbased study was performed to determine the association between polymorphisms of arsenic methylation genes and BC. A total of 216 BC cases and 648 age-and sex-matched healthy controls were enrolled from September 2007 to October 2011. We recruited all subjects from the National Taiwan University Hospital and the Taipei Municipal Wan Fang Hospital. All BC cases were diagnosed by histological confirmation and were from outpatients of the Department of Urology. Also, we recruited non-cancer controls from adult health examinations ( 65-years old) or senior citizen health examinations (>65-years old). Written informed consent was obtained from all study subjects before a questionnaire interview and biological specimen collection. All participants lived in Taipei City, and they drank tap water supplied by the Taipei Water Department of the Taipei City Government; the average arsenic concentration of tap water in Taipei City is 0.7 lg/l. This study was approved by the Research Ethics Committee of the National Taiwan University Hospital in Taipei, Taiwan, and the study was performed in accordance with the World Medical Association Declaration of Helsinki.
Questionnaire interview. A well-trained interviewer using structural questionnaires performed a face-to-face interview with participants in the clinic. The information included demographics and socioeconomic characteristics, lifestyle factors (such as cigarette smoking, alcohol and coffee consumption, and pesticide contact habits), as well as personal and family medical history on the questionnaire.
Biological specimen collection. Blood samples, using ethylenediaminetetraacetic acid (EDTA) vacuum syringes, and spot urine samples were collected at the time of recruitment. Blood samples were separated into buffy coat and plasma, placed in a À80 C freezer and stored until DNA extraction for the identification of polymorphisms of arsenic methylation genes. Urine was immediately transferred to a À20 C freezer and stored until the analysis of arsenic species.
Urinary arsenic species assessment. . The analysis protocol of the arsenic species has been described in a previous study (Hsueh et al., 1998 (NIST, Gaithersburg, Maryland) , and this was analyzed along with the urine specimens from study subjects for the validity of the measurements. The detected value of arsenic of the SRM 2670 standard was 507 6 17 lg/l (n ¼ 4) in our laboratory system. The determination of arsenic species was performed within 6 months after collection to ensure the stability of urinary arsenic profiles (Chen et al., 2002) .
Genotype determination. Genomic DNA was obtained using proteinase K digestion after phenol and chloroform extraction. On the basis of a literature review, we screened the previous studies on AS3MT single nucleotide polymorphisms (SNPs) and arsenic and selected appropriate SNPs. We then checked allele frequency based on Han Chinese in Beijing, China and Asians from the dbSNP Short Genetic Variations, which was provided by the National Center for Biotechnology Information (http:// www.ncbi.nlm.nih.gov/projects/SNP/). A Sequenom MassARRAY platform with iPLEX Gold chemistry (Sequenom, San Diego, California) was used to perform the genotyping for the following: AS3MT rs3740393, rs3740392, rs11191438, rs3740391, rs11191439, rs11191453, rs11191454, rs10748835, and rs1046778; PNP rs1049562, rs1049564, and rs1130650; and GSTO rs2282326, rs4925, rs11509438, rs2297235, and rs156697. Following the manufacturer's guidelines, the specific polymerase chain reaction (PCR) primer and extension primer sequences were designed using the Assay Designer software package (v.4.0). A 1-ll sample of genomic DNA (10 ng/ll) was used for the multiplex PCR reaction; the total reaction mixture had a volume of 5 ll and contained 0.2 U Taq polymerase, 2.5 pmol of each PCR primer, and 25 mM of each deoxynucleotide (dNTP) (Sequenom, Accessory and Enzyme Set). The thermocycler protocol was as follows: 94 C for 4 min; 45 cycles of 94 C for 20 s, 56 C for 30 s, and 72 C for 1 min; and a final step of 72 C for 3 min. Unincorporated dNTPs were deactivated using 0.3 U shrimp alkaline phosphatase. The single base extension reaction was conducted with the iPLEX enzyme, terminator mix, and extension primer mix. The thermocycler protocol was as follows: 94 C for 30 s; 40 cycles of 94 C for 5 s, 56 C for 5 s, and 80 C for 5 s; and a final step of 72 C for 3 min (Sequenom, iPLEX Gold kit). A cation exchange resin was added to remove residual salt from the reactions, and 7 nl of the purified primer extension reaction were loaded onto a matrix pad of a SpectroCHIP (Sequenom). SpectroCHIPs were analyzed using the MassARRAY Analyzer 4, and the clustering analysis was completed with TYPER 4.0 software.
Statistical analysis. The v 2 goodness-of-fit test was used to determine Hardy-Weinberg equilibrium. The SNPs of AS3MT, PNP, and GSTO were divided into 3 classes, wild-type homozygotes, variant heterozygotes, and variant homozygotes. The association between each SNP and BC was analyzed by an additive model (SNPs coded 0, 1, and 2 minor alleles) using a trend test. Cigarette smoking status included never, former, and current.
Former smokers and current smokers were defined as those who had quit cigarette smoking and those who were still smoking at the time of the recruitment, respectively. Urinary total arsenic (lg/l) was defined as the sum of As lated by dividing the concentration of each species by the total arsenic concentration. We used multivariate logistic regression models to estimate the OR and 95% CI to determine the association between genotypes of AS3MT, PNP, and GSTO and the risk of BC after adjustment for covariates. Because polymorphisms of PNP and GSTO were not associated with BC risk, we did not continue to analyze these polymorphisms. Since AS3MT SNPs occur at a specific position in the same DNA sequences, we considered the set of SNP alleles that probably tended to occur together and to show a possible correlation between each other. Therefore, we determined the effect of a genetic segment not only on a single SNP. Linkage disequilibrium (LD) was calculated using the Haploview software package, version 4.1 (Barrett et al., 2005) to show the strength of LD by Lewontin D'. Haplotypes were estimated via the expectation-maximization algorithm using the SAS/Genetics module. We constructed the block on the basis of the Lewontin D' and the distance between each SNP. The additive model (synergy index) (Hosmer and Lemeshow, 1992) and multiplicative model (interaction term) were used to evaluate the combined association of the polymorphism of AS3MT and urinary arsenic profiles in the risk for BC. Statistical Analysis Software (SAS) statistical package (SAS, version 9.4, Cary, North Carolina) was used to conduct all analyses. A 2-sided p < .05 was considered statistically significant.
RESULTS
The distributions of sociodemographic characteristics, lifestyle, cigarette smoking status and urinary arsenic profiles of BC and noncancer controls are shown in Table 1 . The mean age of noncancer controls and BC patients at recruitment was 62.82 and 60.84 years, respectively. Most subjects of noncancer controls and BC patients (78.0% and 78.7%, respectively) were male. Noncancer controls had significantly higher educational levels than BC patients. OR for BC was 2.49 (95% CI, 1.66-3.72) in subjects who were former smokers, and 1.57 (95% CI, 0.99-2.49) in current smokers, compared with those who were nonsmokers. Urinary total arsenic (lg/g creatinine), InAs%, MMA% of BC cases were significantly higher than levels of controls, but urinary creatinine (mg/dl) and DMA% of BC cases were significantly lower. The higher the urinary total arsenic (lg/l) was, the higher OR of BC was after being adjusted for urinary creatinine (mg/dl). The age-gender adjusted OR and 95% CI of InAs%, MMA%, and DMA% for BC were 1.04 (1.02-1.06), 1.05 (1.03-1.07), and 0.96 (0.95-0.97), respectively. All genotype frequencies of AS3MT were fitted with HardyWeinberg equilibrium in noncancer controls. The distributions of genotypes of AS3MT and OR for BC are shown in Table 2 . The AS3MT rs11191438 GG genotype was significantly associated with decreased OR for BC compared with the CC genotype, and OR was 0.54 (95% CI, 0.31-0.92). The AS3MT rs11191438 GG genotype was also significantly associated with decreased OR for BC compared with the AS3MT rs11191438 CC þ CG genotype, and OR was 0.50 (95% CI, 0.31-0.82) (data not shown). Polymorphisms of AS3MT rs10748835 and AS3MT rs1046778 had a similar effect as AS3MT rs11191438 on BC. OR of BC decreased significantly in a dose-response manner only in the AS3MT rs1046778 gene, with an increase in the number of minor alleles,. Polymorphism of the AS3MT rs11191453 TC genotype was significantly associated with increased OR of BC compared with the TT genotype, and OR was 1.41 (95% CI, 1.00-1.98). However, the AS3MT rs11191453 TC þ CC genotype showed a marginally increased OR of BC compared with the TT genotype, where OR was 1.33 (95% CI, 0.96-1.85) (data not shown). Polymorphism of AS3MT rs11191454 had a similar effect as AS3MT rs11191453 on BC risk.
In this study, all Lewontin's D' values between the AS3MT rs3740393, rs3740392, rs11191438, rs3740391, rs11191453, rs11191454, rs10748835, and rs1046778 polymorphisms ranged from 0.99 to 1.0, which indicated LD (Supplementary Figure 1A) , and we also determined r 2 between each pair of polymorphisms (Supplementary Figure 1B) . We evaluated AS3MT haplotypes 1 composed of 4 loci at AS3MTrs3740393, AS3MTrs3740392, AS3MTrs11191438, and AS3MTrs3740391 and AS3MT haplotypes 2 composed of 4 loci at AS3MTrs11191453, AS3MTrs11191454, AS3MTrs10748835, and AS3MTrs1046778. Table 3 shows the distribution of AS3MT haplotypes and the risk of BC. In AS3MT haplotype 2, the maximum number of samples of the AS3MT T-A-G-T haplotype were used as a reference group to calculate the OR for the AS3MT C-G-A-C, T-A-A-C, T-A-A-T, and T-G-G-T haplotypes, which was 1.26 (95% CI, 0.95-1.67), 1.38 (95% CI, 1.02-1.87), and 0.96 (95% CI, 0.63-1.45), respectively. Therefore, we combined the AS3MT C-G-A-C, T-A-A-C, and T-G-G-T haplotypes into a single group; this group was defined as the highrisk haplotype group. The AS3MT T-A-G-T and T-A-A-T haplotype was defined as the low-risk haplotype. Participants with the AS3MT high-risk haplotype 2 had a significantly higher OR than those with an AS3MT low-risk haplotype 2, where the OR was 1.32 (95% CI, 1.05-1.67) in a multivariate-adjusted model. However, AS3MT haplotypes 1 were not related to the risk of BC. When we further analyzed the 3 models adjusted for age, gender, educational level, cigarette smoking, urinary total arsenic, urine creatinine level, and InAs%, and/or MMA% and/or DMA% separately, the OR of BC for AS3MT high-risk haplotype 2 was 1.34 (1.04-1.71), 1.37 (1.06-1.76), and 1.36 (1.05-1.75), respectively. These findings meant no increase in OR of BC for AS3MT risk haplotype 2 after adjusting for each arsenic methylation index separately. On the other hand, when we further adjusted for age, gender, educational level, cigarette smoking, urinary total arsenic, urine creatinine level, and AS3MT risk haplotypes 2, the OR of BC for InAs%, MMA%, and DMA% was 1.01 (1.00-1.03), 1.05 (1.03-1.06), and 0.98 (0.97-0.98), respectively. These findings meant no attenuation of the OR of BC for arsenic methylation indices after adjusting for the AS3MT risk haplotypes 2, and therefore, AS3MT haplotypes and arsenic methylation capacity may have independent effects on BC. After adjusting for covariates, participants with higher urinary total arsenic, InAs% and MMA% or lower DMA% had a significantly higher risk of BC compared with healthy controls in a significant dose-response relationship (Table 4 ). This suggested that higher urinary total arsenic and inefficient arsenic methylation capacity was associated with the risk of BC, consistent with our previous study (Pu et al., 2007) . In addition, the same results were also shown in strata of AS3MT high-risk haplotype 2 or AS3MT low-risk haplotype 2.
Subjects with a MMA% 5.38 and a DMA% >89.56 served as the reference group. A significant trend of progressively increased risk was observed in subjects who had none, either 1, or both of the 2 unfavorable indices in all participants or in a stratification by the high-or low-risk haplotypes 2 of AS3MT (Table 5 ).
Because urinary total arsenic level, arsenic methylation capacity and AS3MT haplotypes 2 affected BC, we wanted to see whether or not there was an interaction between these BC risk factors. Table 6 shows the joint effect of urinary total arsenic level, arsenic methylation capacity indices and AS3MT haplotypes 2 on the OR of BC. Trend analysis revealed progressively increased OR through exposure to no risk factor, either one of the risk factors, or both risk factors, when arsenic methylation capacity indices were adjusted for urinary total arsenic level. Although AS3MT haplotypes 2 tended to interact additively with urinary total arsenic or with methylation capacity indices in modifying OR of BC, none of the interactions was statistically significant. Since AS3MTrs11191438, AS3MTrs11191453, and AS3MTrs1046778 genotypes were associated with BC risk, we further analyzed the interaction of these 3 SNPs of AS3MT in the risk of BC and found a significant dose-response relationship among subjects carrying the AS3MTrs11191438 C/C þ C/G genotypes and AS3MTrs1046778 C/C þ C/T genotypes, who showed a significantly higher OR of BC than those with the AS3MTrs11191438 G/G genotypes and AS3MTrs1046778 T/T genotypes; this association was also found between AS3MTrs11191453 A/A þ A/G genotypes and AS3MTrs1046778 C/C þ C/T genotypes and higher OR of BC (data not shown). We also compared arsenic methylation capacity indices in different AS3MT genotypes, and only found that controls with AS3MTrs11191438 C/C genotype, AS3MTrs10748835 A/A genotype and AS3MTrs1046778 C/C genotype had a significantly higher MMA% than those with the AS3MTrs11191438 C/G genotype, AS3MTrs10748835 A/G genotype and 1046778 C/T genotype, respectively (data not shown). Other genotypes and haplotypes (data not shown) were not related to arsenic methylation capacity indices.
Due to high collinearity between each arsenic methylation capacity index, we performed an analysis using a logistic regression model that included age, sex, InAs%, MMA%, DMA%, and AS3MT genotypes and haplotypes 2, using stepwise selection, and found that age, sex, MMA%, DMA%, and AS3MTrs1046778 polymorphisms were observed in the final model, and that high MMA%, low DMA%, and AS3MTrs1046778 C/C þ C/T were significantly related to an increased OR of BC (Table 7) .
DISCUSSION
To our knowledge, this was the first study to explore the interactions between AS3MT gene polymorphisms and arsenic 
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methylation capacity with regard to the OR of BC, even in a low arsenic exposure area in Taiwan. Polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were significantly related to the risk of BC, while the combination of AS3MT haplotype 2 (AS3MT rs11191453, rs11191454, rs10748835, and rs1046778)'s high-risk haplotype (C-G-A-C, T-A-A-C, and T-G-G-T) was significantly associated with an increased risk of BC after adjustment for age, gender, educational level and cigarette 
Adjusted for age, gender, educational level, cigarette smoking, urinary total arsenic, and urine creatinine level.
þ .05 P < .1; **P < .01; § P < .05 for trend test. Combination of AS3MT haplotypes (listed in the following order: rs11191453, rs11191454, rs10748835 and rs1046778): high-risk haplotypes defined as C-G-A-C, T-A-AC and T-G-G-T, and low-risk haplotypes defined as T-A-G-T and T-A-A-T. Adjusted for age, gender, educational level, cigarette smoking, and urine creatinine level. c Adjusted for age, gender, educational level, cigarette smoking, urinary total arsenic, and urine creatinine level. þ .05 P < .1; *P < .05; **P < .01; § P < .05 for trend test.
smoking. Stepwise multiple logistic regression analyses showed that high MMA%, low DMA%, and AS3MT rs1046778 C/C þ C/T genotype predicted a significantly high OR of BC.
In this study, all participants who lived in Taipei City and the surrounding areas drank tap water from the Taipei Water Department of the Taipei City Government, which had arsenic levels <10 lg/l arsenic standard, according to the WHO drinking water standards (WHO, 2011) . However, besides exposure from drinking water, arsenic, or arsenic species were detected in seafood (Chen et al., 2010) , agricultural rice (Hsu et al., 2012) , edible oil (Chu and Jiang, 2011) , and cereals (Tsai and Jiang, 2011) in Taiwan. Therefore, the exact source of arsenic exposure of the participants in this study was unknown. The mean and standard error of urinary total arsenic level of cases and control were 54.61 6 17.06 and 18.88 6 0.52 lg/g creatinine, respectively, in this study, which were lower than those of cases and controls from arseniasis endemic area (Huang et al., 2008a) . However, with an increase in urinary total arsenic concentration and MMA% and decrease in DMA%, the OR of BC increased significantly in a dose-response manner in this study. These findings are consistent with a recent review that reported that for cancer, most studies found an association between cancer outcomes and higher MMA% and lower DMA% (Kuo et al., 2017) , although these studies had some limitations. A Bangladesh study with a large sample size revealed that principal component 1 accounted for the capacity to produce DMA being associated with age, sex, BMI, AS3MT polymorphism, and skin lesions (Jansen et al., 2016) . This previous study suggested that participants with higher MMA% in their urine were at increased risk for skin lesions, similar to this study in which subjects with higher MMA% had high OR of BC.
The methylation of arsenite is catalyzed mainly by arsenite methyltransferase (AS3MT) using S-adenosylmethionine as a methyl donor (Thomas et al., 2007) . Individual variation of several SNPs of AS3MT results in differences in arsenic methylation capacity, which leads to a different susceptibility to disease caused by arsenic (Agusa et al., 2011; Antonelli et al., 2014) . A genome-wide association study found that AS3MT rs9527 (A), linked to significantly lower DMA%, and AS3MT rs11191659 (A), linked to significantly higher MMA%, were associated with skin lesions in Bangladesh (Pierce et al., 2012) . A southeastern Michigan study found that no single SNP of AS3MT was significantly associated with BC, while it found a significant interaction between AS3MT rs3740400, rs11191438, and rs7085104 polymorphisms and arsenic exposure that increased the OR of BC (Beebe-Dimmer et al., 2012) . In addition, a case-control study showed that no single SNP of AS3MT was significantly associated with BC risk, and also that there was no significant joint effect of AS3MT rs1046778, rs3740391, rs3740392, rs3740393, rs11191439, rs7085854, rs10748835, and rs11191454 polymorphisms and toenail arsenic concentration on the OR of BC in New Hampshire (Lesseur et al., 2012) . A recent study reported that individuals who carried minor alleles of AS3MT rs3740393 (G > C), rs3740390 (G > A) and rs1046778 (T > C) compared with major alleles had significantly lower MMA%, higher DMA%, and lower OR of BC, and that AS3MT rs3740393 GC/CC genotype interacted with historical arsenic exposure (>200 lg/l) and increased the OR of BC in a Chilean population (de la Rosa et al., 2017) . In this study, we found that AS3MT rs11191438 (C > G), AS3MT rs10748835 (A > G), and AS3MT rs1046778 (C > T) were significantly related to risk of BC. Homozygous variant genotypes (dominant) of these SNPs were related to a decreased risk of BC. Our findings are at odds with the results of the Chilean study and may be due to racial differences, but this cannot be confirmed at present.
Arsenic methylation metabolism may be altered due to genetic variation between different races (Fu et al., 2014) . A recent study showed that the polymorphisms of AS3MT rs7085104, AS3MT rs3740393, AS3MT rs3740390, and AS3MT rs1046778 were not related to arsenic methylation capacity, and only found that Combination of AS3MT haplotypes (listed in the following order: rs11191453, rs11191454, rs10748835 and rs1046778): high-risk haplotypes defined as C-G-A-C, T-A-AC and T-G-G-T, and low-risk haplotypes defined as T-A-G-T and T-A-A-T. *P < .05; **P < .01.
varied AS3MT rs3740400 genotypes had significantly different MMA% in the population of Inner Mongolia . Another large-scale study of American Indian population samples showed that the gene product of AS3MT rs12768205, AS3MT rs3740394, and AS3MT rs3740393 catalyzes the methylation of inorganic arsenic to MMA and DMA (Balakrishnan et al., 2017) . A population of Mexican adults exposed to arsenic in drinking water and individuals with AS3MT rs3740393 (GG vs CC genotype), AS3MT rs11191439 (TC vs TT, or CC vs TT genotype) and AS3MT rs11191453 (TT vs TC genotype) had lower DMA%, and higher MMA%, but subjects with AS3MT rs10748835 (GG vs AA or GA vs AA genotype) had lower DMA% and higher MMA% only with high water arsenic exposure (>50 ppb) (Xu et al., 2016) . Interestingly, high arsenic metabolism efficiency has been selected as an adaptive mechanism in northern Chilean people for these populations to survive in an arsenic-rich environment (Apata et al., 2017) . In this study, only partial AS3MT genotypes were found to be correlated with arsenic methylation capacity, but these associations were not consistent with the risk of BC. At present, we cannot explain this, and further investigation is needed. Because many genetic polymorphisms have linkage disequilibrium, and because significant levels are dependent on the frequencies of the genotype, it is difficult to attribute specific gene variations to pathogenicity. A study reported that the most frequent AS3MT haplotype was associated with a high MMA% in Bangladesh, while the most frequent haplotype was associated with a low MMA% and a high DMA% in Argentina (Engstrom et al., 2011) . In addition, AS3MT haplotype status has been found to strongly predict DNA methylation , and alterations in DNA methylation have been suggested as a toxic mechanism of arsenic (Hamadani et al., 2011) . Furthermore, this cited study showed that AS3MT haplotype status modified arsenic methylation capacity and in turn induced arsenicrelated basal cell carcinoma risk (Engstrom et al., 2015) . An interesting study reported that the protective AS3MT haplotype C-T-A (rs3740393, rs3740390, and rs10748835) could have a very strong selective advantage in an arsenic-rich environment (Schlebusch et al., 2013) . In this study, we found that high-risk AS3MT haplotypes 2 increased the OR of BC, but this high-risk AS3MT haplotype was not related to arsenic methylation capacity. Perhaps these haplotypes affect the risk of BC but not by regulating arsenic methylation capacity, so further exploration is needed.
Demographic characteristics and lifestyle such as age, gender, and smoking history could affect arsenic metabolism (Zhang et al., 2014) . Therefore, we considered the influence of these potential factors on arsenic metabolism when evaluating the association between arsenic methylation capacity and BC risk or between AS3MT genotypes and BC risk. We found that high MMA%, low DMA%, and AS3MT rs1046778 C/C þ C/T genotype were significantly associated with increased risk of BC after adjustment for these potential factors in a stepwise logistic regression analysis. These results increased the evidence that less efficient arsenic methylation capacity increases the risk of BC. It was unexpectedly found that AS3MT rs1046778 (T > C) C/C þ C/ T genotype significantly increased the risk of BC, after adjusting for other covariates; however, this result was not in line with the findings of the Chilean study (de la Rosa et al., 2017) . In addition, no significant effect was found for AS3MT rs1046778 and BC risk (Lesseur et al., 2012) . In a recent study, the minor allele of AS3MT rs1046778 (T > C) showed lower InAs% and MMA% and higher DMA%, and was related to high birth weight (Drobn a et al., 2016). According to the above contrary findings, the association between AS3MT rs1046778 polymorphism and BC risk needs to be further explored.
The strength of this study was the analysis of many SNPs of arsenic metabolism-related genes such as AS3MT, PNP, and GSTO, but only a few SNPs were associated with the risk of BC; and only a few SNPs were related to arsenic methylation capacity. This might have been due to insufficient sample size. However, this study had some limitations that need to be discussed when interpreting the results. First, we recruited cases and controls in the same hospitals, but we did not really know whether they came from the same source population. We only evaluated a single spot level of urinary arsenic species, and accuracy might have been questionable. However, assuming that all participants' lifestyle was the same, the values might have been reliable. In addition, because prevalent cases were recruited, in those with the longest disease duration, the possibility that their arsenic metabolism might had been influenced is another limitation, and we also cannot exclude the possibility that the association between arsenic methylation capacity and BC could have been the result and not the cause. Finally, statistical power was a limitation of this study since the low arsenic exposure levels encountered in Taipei, in general, would require the study of a large sample size to evaluate the effects of genetic polymorphisms on arsenic-related BC.
CONCLUSIONS
This study found an association between high urinary total arsenic concentration and inefficient arsenic methylation capacity and the risk of BC. AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC. Taken together, the AS3MT gene polymorphisms, high-risk AS3MT haplotype and arsenic methylation capacity appear to affect the risk of BC independently. The goal is to prevent extensive disease in the arsenic-exposed population by defining susceptible subgroups and exploring the biological mechanisms needed for a large-scale study in future research.
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